Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Ezetimibe therapy: mechanism of action and clinical update

Authors Phan BAP, Dayspring TD, Toth PP

Published Date July 2012 Volume 2012:8 Pages 415—427

DOI http://dx.doi.org/10.2147/VHRM.S33664

Received 7 May 2012, Accepted 23 May 2012, Published 3 July 2012

Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth3

1Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USA

Abstract: The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios.

Keywords: bile, coronary artery disease, ezetimibe, low-density lipoprotein cholesterol, Nieman pick C1 like 1 protein, statin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Dyslipidemia in women: etiology and management

Phan BAP, Toth PP

International Journal of Women's Health 2014, 6:185-194

Published Date: 7 February 2014

Readers of this article also read:

Stress-induced cardiomyopathy (Takotsubo) – broken heart and mind?

Redfors B, Shao Y, Omerovic E

Vascular Health and Risk Management 2013, 9:149-154

Published Date: 17 April 2013

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013

Functionalized graphene oxide for clinical glucose biosensing in urine and serum samples

Veerapandian M, Seo YT, Shin H, Yun K, Lee MH

International Journal of Nanomedicine 2012, 7:6123-6136

Published Date: 18 December 2012

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

Bell DA, Hooper AJ, Watts GF, Burnett JR

Vascular Health and Risk Management 2012, 8:651-659

Published Date: 28 November 2012

The prevention and regression of atherosclerotic plaques: emerging treatments

Kalanuria AA, Nyquist P, Ling G

Vascular Health and Risk Management 2012, 8:549-561

Published Date: 25 September 2012

Characterization of drug-release kinetics in trabecular bone from titania nanotube implants

Aw MS, Khalid KA, Gulati K, Atkins GJ, Pivonka P, Findlay DM, Losic D

International Journal of Nanomedicine 2012, 7:4883-4892

Published Date: 12 September 2012

Very low levels of HDL cholesterol and atherosclerosis, a variable relationship – a review of LCAT deficiency

Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T

Vascular Health and Risk Management 2012, 8:357-361

Published Date: 5 June 2012

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Vascular Health and Risk Management 2010, 6:1023-1037

Published Date: 10 November 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009